Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Entasis Therapeutics Holdings Inc (ETTX)

Entasis Therapeutics Holdings Inc (ETTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,553
  • Shares Outstanding, K 13,292
  • Annual Sales, $ 7,000 K
  • Annual Income, $ -43,850 K
  • 60-Month Beta 2.08
  • Price/Sales 5.46
  • Price/Cash Flow N/A
  • Price/Book 0.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.00
  • Number of Estimates 2
  • High Estimate -0.87
  • Low Estimate -1.13
  • Prior Year -0.99
  • Growth Rate Est. (year over year) -1.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.75 +57.14%
on 03/16/20
5.64 -51.24%
on 03/18/20
-2.41 (-46.71%)
since 02/27/20
3-Month
1.75 +57.14%
on 03/16/20
5.64 -51.24%
on 03/18/20
-2.36 (-46.18%)
since 12/27/19
52-Week
1.75 +57.14%
on 03/16/20
9.25 -70.27%
on 08/19/19
-4.15 (-60.14%)
since 03/27/19

Most Recent Stories

More News
Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its full year 2019 financial...

ETTX : 2.75 (-4.35%)
Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its third quarter financial...

ETTX : 2.75 (-4.35%)
Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced the appointment...

ETTX : 2.75 (-4.35%)
Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Michael...

ETTX : 2.75 (-4.35%)
Entasis Therapeutics Announces Multiple Presentations at ID Week 2019

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced its participation...

ETTX : 2.75 (-4.35%)
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies...

SMMT : 2.44 (+0.83%)
CDTX : 2.47 (+0.41%)
ETTX : 2.75 (-4.35%)
ITRM : 2.79 (unch)
MLNT : 0.4400 (-12.00%)
NBRV : 0.6151 (-6.82%)
PRTK : 3.19 (unch)
SCYX : 0.7238 (-6.00%)
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea

-- 87 million new gonorrhea infections estimated each year; Neisseria gonorrhoeae increasingly resistant to globally recommended treatments and classified by the World Health Organization as a priority...

ETTX : 2.75 (-4.35%)
Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros,...

ETTX : 2.75 (-4.35%)
Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its second quarter financial...

ETTX : 2.75 (-4.35%)
Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros,...

ETTX : 2.75 (-4.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ETTX with:

Business Summary

Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. The company's product pipeline consists of etx2514sul, zoliflodacin, etx0282cpdp and nbp program which are in clinical stage. Entasis Therapeutics Holdings, Inc. is based in...

See More

Key Turning Points

2nd Resistance Point 2.92
1st Resistance Point 2.83
Last Price 2.75
1st Support Level 2.63
2nd Support Level 2.52

See More

52-Week High 9.25
Fibonacci 61.8% 6.38
Fibonacci 50% 5.50
Fibonacci 38.2% 4.61
Last Price 2.75
52-Week Low 1.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar